Mark H Yazer1, Byron Jackson, Jason L Sperry, Louis Alarcon, Darrell J Triulzi, Alan D Murdock. 1. From The Institute for Transfusion Medicine (M.H.Y.,.D.J.T.), Pittsburgh, PA; Department of Pathology (M.H.Y., B.J., D.J.T.), University of Pittsburgh, Pittsburgh, PA; Department of Surgery (J.L.S., L.A., A.D.M.), University of Pittsburgh, Pittsburgh, PA; and Department of Surgery (A.D.M.), Allegheny General Hospital, Pittsburgh, PA.
Abstract
BACKGROUND: The transfusion of cold-stored uncrossmatched whole blood (WB) has not been extensively used in civilian trauma resuscitation. This report details the initial experience with the safety and feasibility of using WB in this setting after a change of practice at a Level 1 trauma center was instituted. METHODS: Up to two units of uncrossmatched group O positive WB that was leukoreduced using a platelet-sparing filter from male donors were transfused to male trauma patients with hypotension secondary to bleeding. Hemolytic marker haptoglobin and reports of transfusion reactions in these patients were followed. Additionally, transfusion volumes and outcomes were compared to a historical cohort of male trauma patients who received at least one red blood cell (RBC) unit, but not WB, during the first 24 hours of admission. RESULTS: There were 47 WB patients who were transfused with a mean (SD) of 1.74 (0.61) WB units. The median haptoglobin concentration on post-WB transfusion Day 1 was 25.1 (9.3) mg/dL in 7 of 30 non-group O recipients. No adverse reactions in temporal relation to the WB transfusions were reported. There were 145 male historical control patients identified who were resuscitated with component therapy; the median volume of incompatible plasma transfused to the WB versus component therapy group was not significantly different (1,000 vs. 800 mL, respectively; p = 0.38); the mean plasma:RBC (0.99 [0.47] vs. 0.77 [ 0.73], respectively; p = 0.006) and platelet:RBC (0.72 [0.40] vs. 0.51 [0.734], respectively; p < 0.0001) ratios were significantly higher in the WB group. CONCLUSION: Transfusion of two units of cold-stored uncrossmatched WB is feasible and seems to be safe in civilian trauma resuscitation. Determining the efficacy of WB with regard to reducing the number of blood products transfused in the first 24 hours or improving recipient survival will require a larger randomized trial. LEVEL OF EVIDENCE: Therapeutic study, level IV.
BACKGROUND: The transfusion of cold-stored uncrossmatched whole blood (WB) has not been extensively used in civilian trauma resuscitation. This report details the initial experience with the safety and feasibility of using WB in this setting after a change of practice at a Level 1 trauma center was instituted. METHODS: Up to two units of uncrossmatched group O positive WB that was leukoreduced using a platelet-sparing filter from male donors were transfused to male traumapatients with hypotension secondary to bleeding. Hemolytic marker haptoglobin and reports of transfusion reactions in these patients were followed. Additionally, transfusion volumes and outcomes were compared to a historical cohort of male traumapatients who received at least one red blood cell (RBC) unit, but not WB, during the first 24 hours of admission. RESULTS: There were 47 WB patients who were transfused with a mean (SD) of 1.74 (0.61) WB units. The median haptoglobin concentration on post-WB transfusion Day 1 was 25.1 (9.3) mg/dL in 7 of 30 non-group O recipients. No adverse reactions in temporal relation to the WB transfusions were reported. There were 145 male historical control patients identified who were resuscitated with component therapy; the median volume of incompatible plasma transfused to the WB versus component therapy group was not significantly different (1,000 vs. 800 mL, respectively; p = 0.38); the mean plasma:RBC (0.99 [0.47] vs. 0.77 [ 0.73], respectively; p = 0.006) and platelet:RBC (0.72 [0.40] vs. 0.51 [0.734], respectively; p < 0.0001) ratios were significantly higher in the WB group. CONCLUSION: Transfusion of two units of cold-stored uncrossmatched WB is feasible and seems to be safe in civilian trauma resuscitation. Determining the efficacy of WB with regard to reducing the number of blood products transfused in the first 24 hours or improving recipient survival will require a larger randomized trial. LEVEL OF EVIDENCE: Therapeutic study, level IV.
Authors: Christine M Leeper; Mark H Yazer; Franklyn P Cladis; Richard Saladino; Darrell J Triulzi; Barbara A Gaines Journal: JAMA Pediatr Date: 2018-05-01 Impact factor: 16.193
Authors: Vassilis L Tzounakas; Alkmini T Anastasiadi; Dimitrios G Karadimas; Redisa A Zeqo; Hara T Georgatzakou; Olga D Pappa; Olga A Papatzitze; Konstantinos E Stamoulis; Issidora S Papassideri; Marianna H Antonelou; Anastasios G Kriebardis Journal: Blood Transfus Date: 2017-04-10 Impact factor: 3.443
Authors: Dan Levin; Maoz Zur; Eilat Shinar; Tzadok Moshe; Avishai M Tsur; Roy Nadler; Mark H Yazer; Danny Epstein; Guy Avital; Shaul Gelikas; Elon Glassberg; Avi Benov; Jacob Chen Journal: Transfus Med Hemother Date: 2021-10-06 Impact factor: 3.747
Authors: Josephine McCullagh; Nathan Proudlove; Harriet Tucker; Jane Davies; Dave Edmondson; Julia Lancut; Angela Maddison; Anne Weaver; Ross Davenport; Laura Green Journal: BMJ Open Qual Date: 2021-07